Home » Authors » Kim Coghill

Articles by Kim Coghill

CuraGen, Seattle Genetics Form Cancer Deal Worth Up To $32M

June 23, 2004

Momenta's Stock Closes Up After IPO Brings In $34.7M

June 23, 2004

CuraGen, Seattle Genetics Form Cancer Deal Worth Up To $32M

June 23, 2004

Momenta's Stock Closes Up After IPO Brings In $34.7M

June 23, 2004

As BioShield Signing Nears, BioShield II Planning Begins

June 22, 2004

As BioShield Signing Nears, BioShield II Planning Begins

June 22, 2004

After Reagan's Death, Pressure Mounts For Human ESC Reform

June 21, 2004

After Reagan's Death, Pressure Mounts For Human ESC Reform

June 21, 2004

Santarus Gets FDA Approval For Rapinex Powder Version

June 17, 2004

Axonyx Begins Second Pivotal Phenserine Trial In Alzheimer's

June 17, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 25, 2025.
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 24, 2025
Clots and metastasis in cancer patients start in the lung
BioWorld MedTech
The lung and thrombosis may play a key role in cancer and metastasis progression, according to a collaborative study led by Cornell University scientists. In the...
Roche looks to grow with sequencing by expansion tech
BioWorld MedTech
Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...